+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 14 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the clinical effectiveness and safety of icotrokinra in adults with moderately to severely active Crohns disease, a long-term condition causing serious inflammation in the intestines. The study is a Phase 2b3 randomized, double-blind, placebo-controlled trial aiming to better understand how well icotrokinra works in treating this condition. Participants will receive one of several oral treatments daily during an initial 12-week induction phase either one of two doses of icotrokinra or a matching placebo. After Week 12, their response status will guide further treatment. Those responding to icotrokinra may be randomized to maintenance doses for up to 40 weeks, with some eligible to join a long-term extension study. Placebo recipients who respond may continue placebo or switch to icotrokinra under specific conditions. Throughout the trial, participants will undergo regular assessments to monitor clinical response, remission, and endoscopic healing at Weeks 12 and 40. Safety will be closely followed up to four weeks after the last dose. The study measures various outcomes including patient-reported remission, inflammatory markers, quality of life, and fatigue. Total participation may extend up to several months depending on treatment phase and eligibility for long-term follow-up.

Age: 18Years +All GendersPhase 2Phase 3
395 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of lebrikizumab, a drug given by injection, in people aged 12 and older with chronic rhinosinusitis and nasal polyps who are also treated with intranasal corticosteroids. This phase 3 trial aims to improve symptoms like nasal congestion and polyp size while monitoring participant safety over about 18 months. Participants receive lebrikizumab injections on different schedules or placebo injections, all along with standard intranasal corticosteroid spray. Adolescents aged 12 to under 18 who weigh at least 40 kg are assigned to open-label lebrikizumab treatment. The study includes multiple groups receiving injections every 2, 4, or 8 weeks to compare outcomes. During the study, participants will undergo assessments including nasal congestion scoring, endoscopic evaluation of nasal polyps, sinus imaging, lung function tests, and symptom questionnaires from the start through 24 weeks. Safety and symptom changes are closely monitored, and the total study duration is approximately 18 months.

Age: 12Years +All GendersPhase 3
202 locations
E

Actively Recruiting

Researchers are studying chronic migraine, a condition causing moderate to severe headaches often on one side of the head, sometimes with nausea, vomiting, and sensitivity to light or sound. This trial evaluates how well the medicine atogepant works compared to a placebo in preventing chronic migraine in participants aged 12 to 17 years. The study also monitors adverse events to assess safety. Participants will be randomly assigned to receive either oral atogepant tablets or placebo once daily for 12 weeks. This double-blind study means neither the participants nor the doctors know who receives the medicine or placebo. Following the treatment, participants will be observed for an additional 4 weeks. During the study, participants will visit hospitals or clinics regularly for assessments. They will complete daily diaries, undergo medical evaluations, blood tests, side effect checks, and questionnaires. The main outcomes include tracking adverse events and changes in monthly migraine days, along with measures of headache days, medication use, and quality of life over approximately 16 weeks.

Age: 12Years - 17YearsAll GendersPhase 3
66 locations
E

Actively Recruiting

Researchers are studying tirzepatide to understand its effects on weight loss and the development of type 2 diabetes in adults who have obesity but do not have diabetes. This phase 4 study takes place in a real-world setting and aims to compare tirzepatide to standard care for these adults who also have at least one health condition related to their weight. The study is sponsored by Eli Lilly and Company and includes participants who are registered patients at participating sites. Participants will be randomly assigned to receive either tirzepatide injections once weekly along with standard care or standard care alone. The study will last about 260 weeks approximately 5 years, allowing researchers to observe long-term effects. The main focus is on how much participants body weight changes from the start of the study after 24 months, as well as whether they develop type 2 diabetes or other health complications related to obesity over 60 months. Throughout the study, participants will have various health measurements taken, including weight, waist size, blood pressure, cholesterol levels, liver enzymes, and quality of life assessments. Researchers will track the time it takes for participants to develop type 2 diabetes and monitor changes in blood sugar control and other health markers. Participants health resource use and overall wellbeing will also be evaluated. These assessments help understand the impact of tirzepatide compared to standard care over the long term.

Age: 18Years +All GendersPhase 4
30 locations
E

Actively Recruiting

This research aims to evaluate the safety and effectiveness of atogepant, a medication currently approved for adults, in treating episodic migraine in children aged 6 to 17 years. The study focuses on pediatric participants who experience moderate to severe migraines with symptoms such as throbbing head pain, nausea, and sensitivity to light and sound. Limited treatment options exist for this age group, so the trial investigates different doses of atogepant to address this need. Participants are divided into groups based on age and receive either a placebo or low or high doses of atogepant tablets once daily for 12 weeks. Children aged 6 to 11 first undergo an open-label pharmacokinetic substudy to determine the appropriate dose before the double-blind treatment period. After the initial 12 weeks, participants either have a follow-up visit 4 weeks after their last dose or can continue receiving atogepant for an additional 52 weeks in an extension study. Throughout the study, participants attend regular visits at hospitals or clinics for medical assessments, blood tests, and questionnaires to monitor the effects of treatment and check for side effects. The main outcomes measured include changes in monthly migraine days and safety through adverse event tracking. The study plans to enroll about 450 children worldwide, with comprehensive monitoring over the treatment and follow-up periods.

Age: 6Years - 17YearsAll GendersPhase 3
98 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of induction therapy using Afimkibart also called RO7790121 in adults with moderately to severely active Crohns disease. This Phase III, multicenter, double-blind, placebo-controlled study aims to determine whether this treatment can induce clinical remission and improve endoscopic response compared to placebo. The trial is led by Hoffmann-La Roche and focuses on participants aged 16 to 80 years who have an inadequate response or intolerance to other Crohns disease treatments. Participants are randomly assigned to one of two groups one group receives Afimkibart initially through intravenous infusion followed by subcutaneous injections, while the other group receives a placebo intravenous infusion followed by Afimkibart subcutaneous injections. The study follows a parallel design with double-blinding to compare the effects of these treatment approaches over a 12-week induction period. During the trial, participants will undergo assessments including Crohns Disease Activity Index scoring, endoscopic evaluations, and symptom tracking such as stool consistency, abdominal pain, and fatigue. Researchers will monitor clinical remission, symptomatic relief, and adverse events up to 30 weeks after baseline. Quality of life will be measured with questionnaires, and biomarker subgroups will be analyzed. The studys total duration extends through 2033, with key measurements taken at week 12.

Age: 16Years - 80YearsAll GendersPhase 3
208 locations
R

Actively Recruiting

Researchers are evaluating the prevention of venous thromboembolism VTE, a serious condition that can occur after a stroke, in immobile patients. This study compares the current standard treatment, Intermittent Pneumatic Compression IPC, with a medical device called the geko device, which uses neuromuscular electrostimulation to increase blood circulation. The study focuses on whether the geko device can better prevent VTE during a 90-day follow-up period after stroke. Participants will be randomly assigned to one of two groups one receiving the geko device and the other receiving standard IPC treatment. The geko devices will be applied to both legs and changed every 24 hours, used continuously for up to 30 days or until the patient regains mobility. The IPC devices will also be applied to both legs and used up to 30 days or until recovery or discharge. Treatment will start soon after randomization. During the study, participants will have leg Doppler ultrasound exams at 7 days optional and 14 days mandatory to check for blood clots. At 14 days, patients will complete a questionnaire about device comfort and health information. At 30 days, medical records will be reviewed for any symptomatic deep vein thrombosis or pulmonary embolism. A final phone follow-up at 90 days will assess recovery, health, mobility, quality of life, and survival. Safety and device effectiveness will also be monitored throughout the study period.

Age: 18Years +All GendersPhase Not Applicable
18 locations
S

Actively Recruiting

Researchers are evaluating the impact of two different default dialysate sodium concentrations on major cardiovascular events and death in adults receiving maintenance haemodialysis for end-stage kidney disease. This pragmatic, cluster-randomised, open-label Phase 4 study compares sodium levels of 137 mmoll and 140 mmoll in real-world dialysis settings across multiple sites globally. Dialysis sites will be randomly assigned to use either a default dialysate sodium concentration of 137 mmoll or 140 mmoll for at least 90% of dialysis sessions. Other aspects of patient care will follow standard local practices. Sites must consent to participate, and individual patients will provide waiver or opt-out consent. The study expects to enroll sites over 5 to 7 years, with each participant followed for approximately 2 to 5 years until the study endpoints are reached. Participants will receive dialysis at their assigned sites with the designated sodium concentration. Researchers will monitor the time to first occurrence of major cardiovascular events or death as the primary outcome. Secondary outcomes include other cardiovascular events and individual components of the composite outcomes. Data collection and patient monitoring will continue throughout the study period, estimated to last around five years per participant.

Age: 18Years +All GendersPhase 4
264 locations
A

Actively Recruiting

Researchers are evaluating multiple treatments for community-acquired pneumonia and other respiratory tract infections in hospitalized patients admitted to intensive care. This adaptive platform trial, called REMAP-CAP, aims to identify the effects of various interventions on patient outcomes, including survival and recovery. It also serves as a flexible research platform to study treatments during respiratory pandemics such as COVID-19, with a specific sub-platform called REMAP-COVID for evaluating COVID-19 treatments in the United States. Participants are randomized to receive one or more interventions from various treatment domains including antibiotics, corticosteroids, antivirals, immune modulators, anticoagulation strategies, and mechanical ventilation approaches. Some interventions have been closed to recruitment while others remain active, and dosing or duration often follows local clinical guidelines or specific protocols. The trial uses an adaptive design that allows modification of treatment assignments based on accumulating data and can study interactions between treatments across domains. During the study, hospitalized patients with respiratory infections will be monitored and assessed for outcomes such as 90-day survival and recovery trajectories, days alive without organ support, and quality of life at six months. Data collected include treatment responses, hospital discharge status, and mortality. The trial is designed to continue enrolling patients adaptively over time, with ongoing evaluation of multiple interventions until conclusive answers about their effects are reached.

Age: 28Days +All GendersPhase 3
408 locations
T

Actively Recruiting

Chronic obstructive pulmonary disease COPD is a common lung condition affecting many adults worldwide, with exacerbations leading to worsening health and hospital admissions. This trial focuses on patients recently discharged after a hospital stay for a COPD exacerbation, aiming to reduce the risk of readmission and improve outcomes during the critical 90-day high-risk period after discharge. The study is a phase 3, multicenter randomized controlled trial addressing an important healthcare challenge and potential cost savings for the NHS. The trial compares a supported rescue pack management plan to standard care. Participants in the supported rescue pack group receive a 5-day rescue pack of prednisolone and antibiotics, a written self-management plan based on the Asthma-Lung UK plan, and twice-weekly automated phone or text symptom assessments for 90 days. Those in the standard care group do not receive rescue packs on discharge but may access them through community care. The trial will monitor the use of rescue packs and support provided during the 90-day period. Participants will be involved in regular symptom monitoring through automated calls or texts and follow-up assessments. Researchers will measure time to first hospital readmission within 90 days as the primary outcome, along with secondary outcomes including readmission frequency, days alive and out of hospital, corticosteroid and antibiotic use, healthcare contacts, quality of life, and cost-effectiveness. Safety monitoring will include adverse events and antimicrobial resistance over an average of 4 years, with participant involvement lasting up to one year for some assessments.

Age: 40Years +All GendersPhase 3
34 locations

1-10 of 14

1